Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2024
-
- participants needed
- 50
-
- sponsor
- M.D. Anderson Cancer Center
Summary
This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or myelodysplastic syndrome.
Description
PRIMARY OBJECTIVE:
I. To obtain preliminary evidence of efficacy as defined by 1-year progression free survival.
SECONDARY OBJECTIVES:
I.To determine safety of this regimen as per National Cancer Institute (NCI) toxicity criteria.
II.To determine time to neutrophil and platelet engraftment. III.To determine incidence of acute and chronic graft versus host disease (GVHD).
IV.To determine relapse incidence. V.To determine non-relapse mortality. VI.To determine overall survival. VII.To determine graft versus host disease-relapse free survival (GRFS).
- OUTLINE
Patients receive venetoclax orally (PO) once daily (QD) on days -22 to -3, busulfan intravenously (IV) over 3 hours on days -20, -13, -6, -5, -4, and -3, and fludarabine phosphate (fludarabine) IV over 1 hour and cladribine IV over 2 hours on days -6 to -3 in the absence of disease progression or unacceptable toxicity. Patients then undergo stem cell transplantation over 1-2 hours on day 0.
After completion of study treatment, patients are followed up at 7 days, at engraftment, at 1, 3, 6, and 12 months, then annually for up to 3 years.
Details
| Condition | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome |
|---|---|
| Treatment | fludarabine phosphate, busulfan, cladribine, Hematopoietic Cell Transplantation, thiotepa, venetoclax |
| Clinical Study Identifier | NCT04708054 |
| Sponsor | M.D. Anderson Cancer Center |
| Last Modified on | 28 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer